Provisional figures on participation in the National Immunisation Programme According to RIVM’s registration system, at least 90% of babies have been vaccinated against mumps, measles and rubella (MMR).
Proposed European PFAS ban officially submitted The Netherlands, Germany, Denmark, Sweden and Norway today took the first formal step towards a European ban on per- and polyfluoroalkyl substances (PFAS) by jointly submitting a restriction proposal to the European Chemicals Agency (ECHA).
Vaccine manufacturer employee contracts poliovirus An employee of vaccine manufacturer Bilthoven Biologicals (BBio) has been infected with a poliovirus. The virus was found in a stool sample provided by the employee. The employee concerned is now in isolation.
National Immunisation Programme: new decline in number of reported cases of disease in 2021 In 2021, fewer people contracted diseases for which vaccines are offered under the National Immunisation Programme (NIP) than before the coronavirus pandemic. This is very likely largely due to the impact of the coronavirus measures, such as social distancing and hand washing.
PFAS levels in drinking water from river water need to be brought down The National Institute for Public Health and the Environment (RIVM) advises to reduce PFAS concentrations in the drinking water in parts of the Netherlands in the coming years. This concerns drinking water produced from river water.
Patient with cutaneous diphtheria in reception centre This week, a refugee from Syria was found to be infected with the diphtheria bacterium. The patient has been treated with antibiotics. The patient’s contacts have been tested and vaccinated.
Higher alert level for Ebola There is an Ebola outbreak in several regions of Uganda that are also frequented by tourists. RIVM therefore asks medical professionals to be alert to symptoms that could indicate Ebola among people who have travelled to Uganda, and to request diagnostics to rule out or confirm Ebola.
Side effect reports National Immunisation Programme 2021 Last year, the Netherlands Pharmacovigilance Centre Lareb received 1,462 reports of possible side effects from vaccines administered under the National Immunisation Programme. As was the case in previous years, no new, disconcerting side effects have
BA.2.75 variant found in the Netherlands The BA.2.75 variant of the coronavirus SARS-CoV-2 has now also been found in the Netherlands. The variant was detected in a sample from 26 June 2022 taken in the region of Noordoost-Gelderland.
Participation in National Immunisation Programme shows slight decrease Participation in the National Immunisation Programme has fallen slightly, showing a decrease of 1 to 2 percentage points.